Drug Ther Bull. 2004 Aug;42(8):57-60.

Which atypical antipsychotic for schizophrenia?

[No authors listed]

Erratum in

Drug Ther Bull. 2005 Apr;43(4):32.

Abstract

Until the early 1990s, first-line drug therapy for patients with acute schizophrenia was usually a traditional antipsychotic, such as haloperidol. As recently as 1997, we recommended that newer, so-called 'atypical' antipsychotic drugs, such as olanzapine and risperidone, should be reserved for patients unable to tolerate traditional drugs. Now, atypical antipsychotics are widely regarded as better than traditional drugs, being generally less likely to cause troublesome extrapyramidal effects or hyperprolactinaemia. Current atypical antipsychotics differ from one another in important respects. Here we consider how important differences in their unwanted-effect profiles may influence the choice between these drugs for patients with schizophrenia.

PMID:: 15310154; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Antipsychotic Agents

LinkOut - more resources

Full Text Sources

Medical

Schizophrenia - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. [Encephale. 2005]
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, et al. Encephale. 2005 Mar-Apr; 31(2):235-46.
Review [Antipsychotics in bipolar disorders]. [Encephale. 2004]
Review [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. Encephale. 2004 Sep-Oct; 30(5):417-24.
Review Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. [Drug Saf. 2004]
Review Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P, Ratner S, Laor N, Weizman A. Drug Saf. 2004; 27(14):1135-56.
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. [Encephale. 2009]
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM, avec le soutien institutionnel du laboratoire Lilly. Encephale. 2009 Sep; 35(4):330-9. Epub 2009 Jul 9.
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. [Health Technol Assess. 2006]
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, et al. Health Technol Assess. 2006 May; 10(17):iii-iv, ix-xi, 1-165.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. [BMC Psychiatry. 2008]
Review Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.
Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. BMC Psychiatry. 2008 Sep 25; 8:84. Epub 2008 Sep 25.
Prevention of coronary heart disease in people with severe mental illnesses: a qualitative study of patient and professionals' preferences for care. [BMC Psychiatry. 2006]
Prevention of coronary heart disease in people with severe mental illnesses: a qualitative study of patient and professionals' preferences for care.
Wright CA, Osborn DP, Nazareth I, King MB. BMC Psychiatry. 2006 Apr 21; 6:16. Epub 2006 Apr 21.
Long term outcome of treating schizophrenia. [BMJ. 2004]
Long term outcome of treating schizophrenia.
Turner TH. BMJ. 2004 Nov 6; 329(7474):1058-9.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Which atypical antipsychotic for schizophrenia?
Which atypical antipsychotic for schizophrenia?
Drug Ther Bull. 2004 Aug ;42(8):57-60.

PubMed
Effects of 24 h ultra-marathon on biochemical and hematological parameters.
Effects of 24 h ultra-marathon on biochemical and hematological parameters.
World J Gastroenterol. 2004 Sep 15 ;10(18):2711-4.

PubMed
Stem cell therapy for Parkinson's disease: where do we stand?
Stem cell therapy for Parkinson's disease: where do we stand?
Cell Tissue Res. 2004 Oct ;318(1):261-73. Epub 2004 Aug 11 .

PubMed
The contribution of body composition, substrates, and hormones to the variabilit...
The contribution of body composition, substrates, and hormones to the variability in energy expenditure and substrate utilization in premenopausal women.
J Clin Endocrinol Metab. 1992 Feb ;74(2):279-86.

PubMed
Integration of novel agents in the treatment of colorectal cancer.
Integration of novel agents in the treatment of colorectal cancer.
Cancer Chemother Pharmacol. 2004 Sep ;54 Suppl 1:S32-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: